CL2016002318A1 - Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits. - Google Patents

Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits.

Info

Publication number
CL2016002318A1
CL2016002318A1 CL2016002318A CL2016002318A CL2016002318A1 CL 2016002318 A1 CL2016002318 A1 CL 2016002318A1 CL 2016002318 A CL2016002318 A CL 2016002318A CL 2016002318 A CL2016002318 A CL 2016002318A CL 2016002318 A1 CL2016002318 A1 CL 2016002318A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
liquid carrier
oral dosage
dosage form
solution
Prior art date
Application number
CL2016002318A
Other languages
English (en)
Inventor
Moshe Rogosnitzky
Morris Aboohi
Original Assignee
Vigorous Solutions Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54145440&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016002318(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vigorous Solutions Ltd filed Critical Vigorous Solutions Ltd
Publication of CL2016002318A1 publication Critical patent/CL2016002318A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01Q—ANTENNAS, i.e. RADIO AERIALS
    • H01Q5/00—Arrangements for simultaneous operation of antennas on two or more different wavebands, e.g. dual-band or multi-band arrangements
    • H01Q5/50—Feeding or matching arrangements for broad-band or multi-band operation
    • H01Q5/55—Feeding or matching arrangements for broad-band or multi-band operation for horn or waveguide antennas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01Q—ANTENNAS, i.e. RADIO AERIALS
    • H01Q1/00—Details of, or arrangements associated with, antennas
    • H01Q1/27—Adaptation for use in or on movable bodies
    • H01Q1/28—Adaptation for use in or on aircraft, missiles, satellites, or balloons
    • H01Q1/288—Satellite antennas
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01Q—ANTENNAS, i.e. RADIO AERIALS
    • H01Q1/00—Details of, or arrangements associated with, antennas
    • H01Q1/36—Structural form of radiating elements, e.g. cone, spiral, umbrella; Particular materials used therewith

Abstract

El objetivo abordado en la presente solicitud corresponde a la necesidad de proporcionar una composición farmacéutica que posea una biodisponibilidad incrementada de sildenafil, de modo de proporcionar en menos tiempo el mismo efecto terapéutico comparado con el proporcionado por una tableta existente en el estado de la técnica, además que permita reducir la dosis efectiva de sildenafil para mitigar sus efectos secundarios no deseados. Como solución se propone una composición farmacéutica en forma de solución líquida que comprende: (a) un portador líquido que comprende agua y entre 20% y 95% de uno o más alcoholes; y (b) citrato de sildenafil disuelto en dicho portador líquido a una concentración entre 7mg/ml y 125 mg/ml. Además se divulga una forma farmacéutica oral y bucal que comprenden a la composición farmacéutica, Kits que comprenden a la composición farmacéutica y métodos para preparar a la composición farmacéutica en forma de solución.
CL2016002318A 2014-03-19 2016-09-14 Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits. CL2016002318A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461955299P 2014-03-19 2014-03-19

Publications (1)

Publication Number Publication Date
CL2016002318A1 true CL2016002318A1 (es) 2017-03-24

Family

ID=54145440

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002318A CL2016002318A1 (es) 2014-03-19 2016-09-14 Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits.

Country Status (24)

Country Link
US (2) US9968609B2 (es)
EP (2) EP3119201B1 (es)
JP (1) JP6744821B2 (es)
KR (1) KR20160137584A (es)
CN (1) CN106132204B (es)
AU (2) AU2015233006B2 (es)
CA (1) CA2942628C (es)
CL (1) CL2016002318A1 (es)
CY (1) CY1120187T1 (es)
DK (1) DK3119201T3 (es)
EA (1) EA032819B1 (es)
ES (1) ES2668915T3 (es)
HR (1) HRP20180773T1 (es)
HU (1) HUE038431T2 (es)
IL (1) IL247840B (es)
LT (1) LT3119201T (es)
MX (1) MX371276B (es)
NO (1) NO2723977T3 (es)
PL (1) PL3119201T3 (es)
PT (1) PT3119201T (es)
RS (1) RS57206B1 (es)
SG (2) SG11201607507VA (es)
SI (1) SI3119201T1 (es)
WO (1) WO2015140748A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2723977T3 (es) 2014-03-19 2018-03-10
JP6902372B2 (ja) * 2017-02-28 2021-07-14 ヱスビー食品株式会社 苦味抑制用組成物
JP2021509114A (ja) 2017-12-26 2021-03-18 エフティーエフ ファーマ プライベート リミテッド Ｐｄｅ ｖ阻害剤のための液体経口処方物
CA3137260A1 (en) * 2019-04-18 2020-10-22 Ellamed Ip & Services Pte. Ltd. Liquid sildenafil citrate compositions
US20220387433A1 (en) * 2019-11-12 2022-12-08 American Regent, Inc. Type v phosphodiesterase inhibitor compositions, methods of making them and methods of using them in preventing or treating elevated pulmonary vascular pressure or pulmonary hemorrhages

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5785984A (en) * 1993-02-05 1998-07-28 Kao Corporation Taste-modifying method and bitterness-decreasing method
CN1065415C (zh) * 1993-02-05 2001-05-09 花王株式会社 蛋白质和类脂复合体用于改善味觉的用途
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
TWI223598B (en) 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
US6531114B1 (en) 1999-04-06 2003-03-11 Wm. Wrigley Jr. Company Sildenafil citrate chewing gum formulations and methods of using the same
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
TW200400821A (en) * 1999-11-02 2004-01-16 Pfizer Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
EP1237538A2 (en) * 1999-11-18 2002-09-11 Natco Pharma Limited An improved pharmaceutical composition for treating male erectile dysfunction
WO2001056547A2 (en) 2000-02-04 2001-08-09 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
WO2002005820A1 (en) 2000-07-19 2002-01-24 Lavipharm Laboratories, Inc. Sildenafil citrate solid dispersions having high water solubility
US20030216407A1 (en) 2002-01-31 2003-11-20 Pfizer Inc. Use of PDE5 inhibitors in the treatment of scarring
US7611728B2 (en) 2003-09-05 2009-11-03 Supernus Pharmaceuticals, Inc. Osmotic delivery of therapeutic compounds by solubility enhancement
US20070065394A1 (en) 2003-11-17 2007-03-22 Pinney Virginia R Compositions effective in altering the perception of malodor
CN1925860A (zh) * 2004-01-05 2007-03-07 特瓦制药工业有限公司 制备西地那非碱及其柠檬酸盐的方法
WO2005067936A2 (en) 2004-01-05 2005-07-28 Teva Pharmaceutical Industries Ltd. Methods for the production of sildenafil base and citrate salt
US7727565B2 (en) 2004-08-25 2010-06-01 Cadbury Adams Usa Llc Liquid-filled chewing gum composition
GT200600112A (es) 2005-03-14 2006-11-29 Composiciiones de tigeciclina y metodos de preparacion
US7556487B2 (en) 2006-03-29 2009-07-07 Intergum Gida Sinayi ve Ticaret A.S. Apparatus for making center-filled chewing gum pieces
FR2906140B1 (fr) * 2006-09-22 2008-12-05 Philippe Perovitch Forme galenique pour l'administration par voie trans-muqueuse de principes actifs
EP2008530B1 (de) 2007-06-19 2011-01-19 Symrise AG Aromakomposition zum Verringern oder Unterdrücken von unerwünschtem bitteren und adstringierenden Eindruck
EP2072044A1 (en) * 2007-12-19 2009-06-24 Abbott GmbH & Co. KG Pharmaceutical dosage form comprising a liquid or flowable core composition
WO2009125415A1 (en) 2008-04-07 2009-10-15 Hetero Research Foundation Amorphous form of sildenafil citrate
FR2939321B1 (fr) 2008-12-05 2011-08-26 Philippe Perovitch Dispositif de conditionnement et d'administration de principes actifs en solution hydro-alcoolique.
US8642270B2 (en) 2009-02-09 2014-02-04 Vm Institute Of Research Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer
DE102010049708A1 (de) * 2010-10-28 2012-05-03 Hexal Ag Orale pharmazeutische Filmformulierung für bitter schmeckende Arzneistoffe
AU2012347997B2 (en) * 2011-12-05 2017-07-20 Suda Limited Oral spray formulations and methods for administration of sildenafil
GB2497933B (en) 2011-12-21 2014-12-24 Londonpharma Ltd Drug delivery technology
CA3189252A1 (en) * 2012-05-16 2013-11-21 Techfields Pharma Co., Ltd. High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions
US9186361B2 (en) 2013-03-15 2015-11-17 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
NO2723977T3 (es) 2014-03-19 2018-03-10

Also Published As

Publication number Publication date
EA032819B1 (ru) 2019-07-31
SG11201607507VA (en) 2016-10-28
NO2723977T3 (es) 2018-03-10
EP3372083A1 (en) 2018-09-12
JP2017508764A (ja) 2017-03-30
US20170049776A1 (en) 2017-02-23
EP3119201A4 (en) 2017-03-15
CN106132204B (zh) 2019-08-20
CN106132204A (zh) 2016-11-16
AU2015233006B2 (en) 2018-07-19
SI3119201T1 (en) 2018-07-31
PT3119201T (pt) 2018-06-15
IL247840B (en) 2019-03-31
WO2015140748A3 (en) 2015-12-17
WO2015140748A2 (en) 2015-09-24
CA2942628A1 (en) 2015-09-24
JP6744821B2 (ja) 2020-08-19
HRP20180773T1 (hr) 2018-06-15
CY1120187T1 (el) 2018-12-12
PL3119201T3 (pl) 2018-08-31
MX371276B (es) 2020-01-23
EP3119201A2 (en) 2017-01-25
US9968609B2 (en) 2018-05-15
ES2668915T3 (es) 2018-05-23
AU2015233006A1 (en) 2016-11-03
RS57206B1 (sr) 2018-07-31
AU2018250378A1 (en) 2018-11-08
LT3119201T (lt) 2018-05-10
SG10201808038TA (en) 2018-10-30
KR20160137584A (ko) 2016-11-30
AU2018250378B2 (en) 2020-05-14
US20180233823A1 (en) 2018-08-16
DK3119201T3 (en) 2018-05-28
EA201691871A1 (ru) 2017-03-31
CA2942628C (en) 2022-06-07
HUE038431T2 (hu) 2018-10-29
MX2016012154A (es) 2016-12-15
US10211534B2 (en) 2019-02-19
EP3119201B1 (en) 2018-03-14

Similar Documents

Publication Publication Date Title
CL2016002318A1 (es) Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits.
EA201691151A1 (ru) Соединения для лечения пациентов с ros1-мутантными раковыми клетками
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
NI201600058A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
GT201500030A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
GT201500053A (es) Composicion farmaceutica recubierta que contiene regorafenib
MA38399A1 (fr) Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique
PE20140051A1 (es) Metodos y productos de farmaco para tratar enfermedad de alzheimer
CL2019002190A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984)
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
PE20142043A1 (es) Enfoque metabolico selectivo para aumentar la biodisponibilidad oral de la fenilefrina y otros bioactivos metabolicos
AR091351A1 (es) Formulaciones de bromocriptina, metodo para mejorar el control glucemico y metodo para la fabricacion
CL2015003468A1 (es) Composicion solida para administracion oral conteniendo acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d.
MX2016008841A (es) Moduladores heterociclicos de la sintesis de lipidos para su uso contra el cancer e infecciones virales.
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
PE20151300A1 (es) Composicion antifungica topica para el tratamiento de onicomicosis
EA201992382A3 (ru) Пероральная таблетированная фармацевтическая композиция двойного применения на основе сульфатных солей и способы ее применения
AR088845A1 (es) Composiciones farmaceuticas que contienen 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para el tratamiento de las enfermedades y las afecciones de la piel
TR201819662T4 (tr) Çocukluk çağı hipertansiyon tedavisinde kullanılan enalapril içeren ağızda dağılan film bileşimi.
AR107298A1 (es) Método de purificación
RU2014106575A (ru) Способ профилактики кровотечения при миомэктомии
AR100153A1 (es) Medicamento